Adagrasib is a small molecule inhibitor of KRAS G12C mutant isoform indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.